PrimeRFP SCOUT · Federal Contract Recompete Brief

75N91018F00059 — EBOLA VIRUS AND OTHER INFECTIOUS DISEASES

EBOLA VIRUS AND OTHER INFECTIOUS DISEASES is a federal award for Department of Health and Human Services (HHS) held by LEIDOS BIOMEDICAL RESEARCH, INC.. Estimated value $64.9M ($13.1M obligated). Current period of performance ends Sep 21, 2028.

$64.9M
Estimated Value
$13.1M
Obligated
Sep 21, 2028
PoP End / Expires

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

LEIDOS BIOMEDICAL RESEARCH, INC. holds $2.3B across 187 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 3 related awards under parent HHSN261201500003I. Recompete timing centers on the Sep 21, 2028 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

Federal
Contract number75N91018F00059
AgencyDepartment of Health and Human Services (HHS)
IncumbentLEIDOS BIOMEDICAL RESEARCH, INC.
UEIHV8BH9BPG8Y9
NAICS561210

No full NAICS 561210 intel page yet. Browse NAICS intelligence

PSCM1HA
Parent IDIQ / IDVHHSN261201500003I
PoP end (current)Sep 21, 2028
Obligated$13.1M

EBOLA VIRUS AND OTHER INFECTIOUS DISEASES

Recompete timing

Public
Expiring in 766 days

Current PoP ends Sep 21, 2028 (766 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Mar 21, 2027.

Watch this contract — one email →

Incumbent footprint

Public record

LEIDOS BIOMEDICAL RESEARCH, INC.$2.3B obligated across 187 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$2.3B · 100% of firm total
Open full company profile

Related awards

Same parent · incumbent
75N91018F00071
HHSN261201500003I; HHSN26100071; 400.021.0071.0001; NCI CBIIT; APPROPRIATED; EXPAND DATA C…
$67.0M
Aug 31, 2027
75N91018F00073
PDX PANELS FROM COMMON TUMORS
$67.9M
Sep 25, 2027
75N91018F00077
CELL-BASED IMMUNOTHERAPY PRODUCTS
$53.5M
Aug 29, 2029

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open LEIDOS BIOMEDICAL RESEARCH, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75N91018F00059?

75N91018F00059 (EBOLA VIRUS AND OTHER INFECTIOUS DISEASES) is a Department of Health and Human Services (HHS) award with an estimated value of $64.9M, currently held by LEIDOS BIOMEDICAL RESEARCH, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75N91018F00059?

LEIDOS BIOMEDICAL RESEARCH, INC. is the incumbent with $2.3B across 187 related awards in SCOUT’s public footprint. The current period of performance ends Sep 21, 2028.

When does 75N91018F00059 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 21, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/HHSN261201500003I-75N91018F00059